[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nervous-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nervous-system-diseases":860},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,69,101,142,180,232,260,284,311,392,412,423,440,471,500,530,581,608,639,692,712,745,765,795,825],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":42,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100053565",false,"NCT07587242","A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","SAFARI44","Key Inclusion Criteria:\n\n* Ambulatory males with clinical and genetic diagnosis of DMD\n* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping\n* 7 to 16 years of age at time of consent\n* TTR and NSAA assessment completed within the protocol specified parameters at Screening\n* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.\n\nKey Exclusion Criteria:\n\n* Previous treatment cell or gene therapy.\n* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).\n* Lab values outside of the protocol specified range at Screening\n* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:\n* Less than 1 month, for growth hormone and\u002For testosterone\n* Less than 6 months for givinostat","MALE","7 Years","16 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping",[28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Muscular Dystrophies","Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)","Muscular Disorders, Atrophic","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Diseases (NMD)","Nervous System Diseases","Genetic Diseases","X-Linked","Hereditary","Neonatal Disease","Duchene Muscular Dystrophy","Congenital","DMD",[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"AOC","AOC 1044","AOC 1044-CS3","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","SAFARI","SAFARI 44","Avidity","Avidity Biosciences","Exon Skipping Therapy","Avidity Biosciences Inc., A Novartis Company","del-zota","NOT_YET_RECRUITING","2026-07-10",{"date":60,"type":61},"2026-07-13","ACTUAL",{"date":63,"type":22},"2026-06",{"date":65,"type":22},"2030-07",{"name":67,"class":68},"Avidity Biosciences, Inc.","INDUSTRY",{"id":70,"slug":4,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":75,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":99,"locationsCount":100},"100612219","NCT07250737","Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping","Key Inclusion Criteria\n\nRollover Participants\n\n* Completed Study EXPLORE44-OLE Treatment Period (through W102)\n* No significant tolerability issues with AOC 1044\n\nNew (Non-Rollover) Participants\n\n* Permanently residing in the US and have a US primary health care provider\n* Documented dystrophin gene mutation that is amenable to exon 44 skipping\n* Age 2 or older at the time of consent\n* If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response\n\nKey Exclusion Criteria\n\nRollover Participants\n\n• Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements\n\nNew (Non-Rollover) Participants\n\n* Recently treated with or on a clinical study for another investigation drug\n* Serious respiratory or cardiac dysfunction, or nearing end of life\n* Screening laboratory parameters do not meet protocol requirements\n* History of multiple drug allergies or to any component of AOC 1044\n* Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE","2 Years","EXPANDED_ACCESS","The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.",[30,79,32,80,34,81,82,28,83],"Muscular Diseases","Neuromuscular Diseases","Genetic Diseases, Inborn","Genetic Diseases, X-Linked","Muscular Dystrophy, Duchenne",[52,53,44,46,47,48,49,85,86,41,87,88,89,90,91,92,93,94],"Del-zota","delpacibart zotadirsen","exon skipping therapy","dystrophin","managed access","expanded access","pre-approval access","compassionate use","MAP","EAP","AVAILABLE","2026-06-26",{"date":98,"type":61},"2026-06-29",{"name":67,"class":68},14,{"id":102,"slug":4,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":125,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":141},"100472474","NCT05432349","Rett Syndrome Registry","Rett Syndrome Real World Data Observational Registry","RSR","Inclusion Criteria:\n\n* Male or female with a pathologic loss of function alteration of MECP2\n\nExclusion Criteria:\n\n* Male or female with a gain of function alteration of MECP2, including those with MEPC2 duplication or triplication","ALL","0 Years","99 Years",{"count":112,"type":22},3000,"5 Years","OBSERVATIONAL","The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett syndrome and to facilitate the development of better clinical trials and other aspects of the drug development path for Rett syndrome.",[117,118,119,82,120,121,122,123,124,34],"Rett Syndrome","Rett Syndrome, Atypical","Genetic Disease","Intellectual Disability","Neurobehavioral Manifestations","Neurologic Manifestations","Neurologic Disorder","Neurodevelopmental Disorders",[126,127,128,129,130],"Rett syndrome","MECP2","Neurodevelopmental disorder","Registry","Natural History Study","RECRUITING",{"date":133,"type":61},"2026-06-30",{"date":135,"type":61},"2022-08-02",{"date":137,"type":22},"2028-07",{"name":139,"class":140},"International Rett Syndrome Foundation","OTHER",19,{"id":143,"slug":4,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":155,"conditions":156,"keywords":165,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100644654","NCT07674511","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury","Impact of Transcutaneous Spinal Stimulation on Blood Pressure and Orthostasis in Spinal Cord Injury: Short and Long-Term Effects","(SCI)","Inclusion Criteria:\n\n* Individuals with a SCI ≥ 1 year after injury\n* Injury level ≥ T6 (thoracic level)\n* AIS grade A-C\n* Cardiovascular dysfunction characterized by one or more of the following:\n\n  1. Persistent hypotension (SBP \\\u003C 90mmHg)\n  2. Orthostatic hypotension (OH, a drop of 20\u002F10 mmHg in SBP\u002FDBP within 5 minutes of standing\u002Fupright positioning).\n\nAdditionally, experiencing orthostatic symptoms in daily life and\u002For requiring medication to manage OH.\n\nExclusion Criteria:\n\n* Current illness (e.g., infection, a pressure injury that might interfere with the intervention)\n* Ventilator-dependent\n* History of implanted brain\u002Fspine\u002Fnerve stimulators\n* Cardiac pacemaker\u002Fdefibrillator or intra-cardiac lines\n* Significant coronary artery or cardiac conduction disease, a recent history of myocardial infarction\n* History of seizures\n* pregnancy\n* Insufficient mental capacity to understand and independently provide consent\n* Deemed unsuitable by the study physician","18 Years","75 Years",{"count":152,"type":22},10,[154],"NA","The purpose of this study is to learn whether stimulation applied to the spinal cord through the skin (called transcutaneous spinal stimulation) can help control blood pressure in people with a spinal cord injury.\n\nThe main questions this study attempts to solve:\n\n1. What are the immediate effects of spinal cord transcutaneous stimulation on BP?\n2. Does stimulation produce lasting improvements in BP regulation and subsequently, daily function?",[157,158,159,160,161,162,163,34,164],"Spinal Cord Injuries","Hypotension","Orthostatic Hypotension","Spinal Cord Diseases","Cardiovascular Diseases","Trauma, Nervous System","Central Nervous System Disease","Blood Pressure",[166,167,168,169,170],"transcutaneous spinal cord stimulation","spinal stimulations","orthostatic hypotension","blood pressure","neuromodulation","2026-06-24",{"date":98,"type":61},{"date":174,"type":22},"2026-09",{"date":176,"type":22},"2028-12",{"name":178,"class":140},"Kessler Foundation",1,{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":217,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":231},"100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":188,"type":22},500,[154],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[192,34,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216],"Neurologic Disorders","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[218,219,195,196,220,221,209,222,200,215,212,223],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":96,"type":61},{"date":226,"type":61},"2016-06",{"date":228,"type":22},"2028-07-31",{"name":230,"class":68},"MD Stem Cells",3,{"id":233,"slug":4,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":250,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":258,"locationsCount":179},"100644087","NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.",{"count":240,"type":22},706,[154],"MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[34,244,161,245,246,247,202,248,195,249],"Cerebrovascular Disorders","Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage, Hypertensive","Hemorrhagic Stroke, Intracerebral",[251,252,253],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","2026-06-18",{"date":171,"type":61},{"date":63,"type":22},{"date":137,"type":22},{"name":259,"class":140},"Xuanwu Hospital, Beijing",{"id":261,"slug":4,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":280,"leadSponsor":282,"locationsCount":231},"100643617","NCT07626229","Domain-Specific Large Language Model Assistance for Emergency Neurological Diagnosis and Treatment（DEMAND）","Domain-Specific Large Language Model Assistance for Emergency Neurological Diagnosis and Treatment: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years;\n* Presentation to the emergency neurology service with acute neurological symptoms;\n* Written informed consent provided by the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n* Presentation primarily for trauma;\n* Pregnancy;\n* Requiring immediate life-saving interventions;\n* Estimated life expectancy of less than 30 days;\n* Participation in another clinical trial within the previous 30 days or in a trial that could interfere with the study or outcome assessment;\n* Any condition that, in the opinion of the investigators, would interfere with the conduct of the trial or the interpretation of the results.",{"count":267,"type":22},1360,[154],"This study will evaluate whether Xuanwu-NeuroAid 2.0, a large language model for emergency neurology, can improve 30-day diagnostic quality in adults with acute neurological symptoms. Physicians will be randomly assigned to AI-assisted care or usual care. In the AI-assisted group, the model will provide diagnostic and management suggestions, while physicians will make all final clinical decisions. The usual-care group will receive standard emergency neurology care without large language model assistance.",[34],[272,273,274,275],"Large Language Model","Emergency Neurology","Diagnostic","Acute Neurological Symptoms","2026-06-09",{"date":278,"type":61},"2026-06-11",{"date":276,"type":61},{"date":281,"type":22},"2026-08-30",{"name":283,"class":140},"Capital Medical University",{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":291,"sex":108,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":179},"100384501","NCT04286516","Brain Connections for Arm Movement After Stroke","Brain Areas That Control Reaching Movements After Stroke: Task-relevant Connectivity and Movement-synchronized Brain Stimulation","CAM","Inclusion Criteria:\n\nInclusion Criteria (control participants):\n\n* Be 45-90 years of age\n* Have adequate language and neurocognitive function to participate in training and testing\n* Be medically stable to participate in the study\n* Be English speaking\n\nInclusion Criteria (participants with stroke):\n\n* Be 45-90 years of age\n* Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other possible diagnosis\n* Stroke onset at least 6 months before enrollment\n* Subcortical stroke (ex: internal capsule, deep white matter of posterior frontal lobe)\n* Present with mild to moderate arm dysfunction\n* Be medically stable to participate in the study\n* Be English speaking\n\nExclusion Criteria:\n\n(for both groups)\n\n* Unable to give informed consent\n* Have a serious complicating medical illness that would preclude participation\n* Contractures or orthopedic problems limiting range of joint motion in the potential study arm or other impairments that would interfere with the study activities\n* Visual loss such that the subject would not be able to see the test patterns on the robot computer monitor\n* Unable to comply with requirements of the study\n* Enrollment in another greater-than-minimal risk study\n* Presence of medical condition or implant that prevents safe administration of TMS or MRI\n* Pregnancy",true,"45 Years","90 Years",{"count":295,"type":22},76,[154],"The purpose of this study is to use Transcranial Magnetic Stimulation (TMS) while subjects are making reaching movements in a robotic arm device in order to discover how different brain areas control movement before and after stroke and when these brain areas are most sensitive to TMS.",[195,299,300,34,161],"Brain Disease","Central Nervous System Diseases","2026-05-28",{"date":303,"type":61},"2026-06-02",{"date":305,"type":61},"2020-01-10",{"date":307,"type":22},"2027-06-01",{"name":309,"class":310},"VA Office of Research and Development","FED",{"id":312,"slug":4,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":108,"minAge":317,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":323,"conditions":324,"keywords":356,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":231},"100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","3 Years","21 Years",{"count":320,"type":22},24,[322],"PHASE1","This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,300,34,350,351,352,353,354,355],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[357,358,326,359,360,361,362,363,364,365,366,367,368,369,370,371,328,372,373,374,375,376,377,378,379,352,351,380,381,382],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-05-13",{"date":385,"type":61},"2026-05-15",{"date":387,"type":61},"2019-09-12",{"date":389,"type":22},"2027-09-01",{"name":391,"class":140},"M.D. Anderson Cancer Center",{"id":393,"slug":4,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":179},"100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":399,"type":22},512,[154],"This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[195,244,349,34,245,300],"2026-05-11",{"date":405,"type":61},"2026-05-14",{"date":407,"type":61},"2024-05-27",{"date":409,"type":22},"2026-06-03",{"name":411,"class":140},"University of Southern Denmark",{"id":413,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":26,"conditions":416,"keywords":417,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":421,"leadSponsor":422,"locationsCount":4},"100638788",{"count":21,"type":22},[25],[28,29,30,31,32,33,34,35,36,37,38,39,40,41],[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"2026-05-08",{"date":405,"type":61},{"date":63,"type":22},{"date":65,"type":22},{"name":67,"class":68},{"id":424,"slug":4,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":150,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":179},"100539440","NCT06303869","Deep Brain Stimulation Motor Ventral Thalamus (VOP\u002FVIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke","Inclusion Criteria:\n\n1. Participants must have suffered a single, ischemic, or hemorrhagic stroke more than 6 months before the time of enrollment with dysarthria as a result.\n2. Participants must be between the ages of 18 and 75 years old. (Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing).\n3. English speaker.\n4. Participant must score ≤ 80% in at least 4 categories of the perceptual speech assessment (speech intelligibility, listener effort, speech naturalness, articulatory precision, speech rate, overall voice quality, and\u002For overall speech severity). OR ≤ 80% in at least 3 categories of the perceptual speech assessment AND ≤ 27 on the Communicative Participation Item Bank.\n\nExclusion Criteria:\n\n1. Patients who refuse participation in the study.\n2. Patients with gross anatomical variances in MR imaging or cerebral vascular accidents involving thalamic and cerebellar areas.\n3. Patients with no clinical condition to undergo DBS implantation or highly dependent on anticoagulation therapy.\n4. Patients who cannot undergo pre-operative MRIs or could not complete the pre-operative assessments.\n5. Participants must not have any serious disease or disorder (ex. neurological condition other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) or cognitive impairments that could affect their ability to participate in this study.\n6. Female participants of child-bearing age must not be pregnant, planning to become pregnant for the next 9 months, or breast feeding.\n7. Participants must not be receiving anticoagulants.\n8. Severe claustrophobia.\n9. Participants must not be on anti-spasticity or anti-epileptic medications for the duration of the study.\n10. Participants who have been deemed inappropriate for participation based upon results from the Brief Symptoms Inventory (BSI-18) and discussions with the Principal Investigator and a study physician\n11. Evaluation to sign consent form score \\<12.\n12. MRI contraindications (excluding subjects who are pregnant, who have metal in any portion of their body, have medical complications, cardiac pacemaker, cochlear implant, aneurysm clip, certain IUDs, or known problems of claustrophobia).\n13. Medications with common cognitive side-effects.\n14. Bleeding disorders or platelet dysfunction (e.g., from regular aspirin usage).\n15. Patients must not have any lesions in the lower motoneuron causing flaccid dysarthria.",{"count":152,"type":22},[154],"The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.",[195,299,300,34,161],"2026-05-05",{"date":418,"type":61},{"date":435,"type":61},"2025-06-20",{"date":437,"type":22},"2029-12",{"name":439,"class":140},"Jorge Gonzalez-Martinez",{"id":441,"slug":4,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":108,"minAge":447,"maxAge":448,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":457,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":470},"100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.","60 Years","85 Years",{"count":450,"type":22},180,[154],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[454,212,349,300,34,193,455,456],"Alzheimer's Disease","Neurocognitive Disorders","Mental Disorder",[458,459,460,212],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":463,"type":61},"2026-04-23",{"date":465,"type":61},"2023-05-15",{"date":467,"type":22},"2027-06-30",{"name":469,"class":68},"Advanced Technology & Communications",11,{"id":472,"slug":4,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":291,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":484,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":499},"100419829","NCT04746820","Functional Near-infrared Spectroscopy in Unconscious Patients","Prognostic Value of Functional Near-infrared Spectroscopy in Unconscious Neurocritical Care Patients- a Prospective Pilot Study","fNIRS","Inclusion Criteria - experimental group:\n\n* Patients of either sex with severe hemorrhagic, ischemic stroke or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation treated at the Institute of Intensive Care Medicine, University Hospital Zurich\n* Unconsciousness (GCS \\\u003C 9) or sedated to the severity of the disease (for the subgroup of patients included in the fNIRS-EEG measurement unconscious patients are defined as not responding to verbal stimuli. The motor response to pain should be one of the following: no response to pain \u002F extensor response \u002F flexor response \u002F localize to pain)\n* Age ≥ 18 years\n* Signed informed consent obtained from legal representative\n* Measurement logistically and technical possible within the first 7 days after admission\n\nInclusion Criteria - control group:\n\n* Subjects of either sex\n* Conscious (GCS = 15)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria - experimental group:\n\n* Patients age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease\n* Concomitant instable critical illness (e.g. sepsis, multi-organ failure, hemodynamic or respiratory instability)\n* Acute status epilepticus\n* Clinical recovery (GCS ≥ 9) or death before enrolment of the study\n\nExclusion Criteria - control group:\n\n* Subjects age \\\u003C 18 years\n* Positive pregnancy test for any female of childbearing potential or breast feeding female\n* Previous auditory complaints or any ear diseases\n* No response detectable at Erb's point in SSEP (e.g. due to peripheral nerve lesions, edema etc.)\n* Any history of previous cerebral or brainstem disease",{"count":479,"type":22},30,[154],"The study design is a single-center prospective pilot study. Hypothesis: Results of cerebral fNIRS examination in unconscious patients with severe hemorrhagic or ischemic stroke in the ICU are congruent with the results of SSEP and AEP. Hence, making it a potential prognostic tool for unconscious ICU patients.\n\nIn a specific subgroup of unconscious patients after cardiac arrest and cardiopulmonary resuscitation the fNIRS measurement is congruent with the results of electroencephalography (EEG).\n\nThe primary purpose of this study is to evaluate the agreement of the results of fNIRS examination to those of evoked potentials and EEG in unconscious ICU patients with severe hemorrhagic, or ischemic strokes or hypoxic brain injury after cardiac arrest and cardiopulmonary resuscitation.\n\nfNIRS will be compared to evoked potentials in an experimental group consisting of unconscious neuro-intensive care patients and in a control group consisting of healthy, conscious subjects.\n\nTo compare fNIRS with evoked potentials there are two test phases:\n\n1. The cerebral response to a somatosensory stimulus (peripheral nerve stimulation) is measured by fNIRS and SSEP\n2. The cerebral response to an auditory stimulus is measured by fNIRS and AEP\n\nTo avoid biases the following has to be considered:\n\n* The timing of the measurements plays an important role. A time difference between compared measurements can influence the outcome significantly due to deterioration or recovery of the neuronal network during the time gap. Therefore, fNIRS and evoked potentials will be measured simultaneously.\n* If the compared measurement methods are conducted by the same researcher the possibility of bias is high. Hence, two different researcher will conduct each one measurement without knowing the results of each other during the measurement.",[34,483],"Healthy Subjects",[485,486,487,488,489,490],"severe cerebral hemorrhage","ischemic stroke","unconscious neurocritical care patients","functional near-infrared spectroscopy","evoked potentials","electroencephalography",{"date":492,"type":61},"2026-04-27",{"date":494,"type":61},"2020-01-15",{"date":496,"type":22},"2026-12-31",{"name":498,"class":140},"Emanuela Keller",2,{"id":501,"slug":4,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":515,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":529},"100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":508,"type":22},282,[154],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[195,244,349,34,245,512,513,514],"Ischemic Stroke","Infarction","Medium Vessel Occlusion",[516,517,195,518,519],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":522,"type":61},"2026-04-16",{"date":524,"type":61},"2026-01-06",{"date":526,"type":22},"2030-05-01",{"name":528,"class":140},"The Second Hospital of Anhui Medical University",6,{"id":531,"slug":4,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":448,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":557,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":100},"100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease",{"count":537,"type":22},60,[25],"This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[541,33,542,543,193,80,544,545,34,546,547,548,549,550,551,552,553,554,555,556],"Neuromuscular Disease","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Nerve Disorders","Nervous System Disease","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[558,549,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR",{"date":522,"type":61},{"date":576,"type":61},"2024-11-22",{"date":578,"type":22},"2028-08",{"name":580,"class":68},"Intellia Therapeutics",{"id":582,"slug":4,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":11,"sex":108,"minAge":588,"maxAge":110,"enrollmentInfo":589,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":179},"100416112","NCT04698421","Collection of Biological Samples From Patients With Rare Neurological Diseases","Prospective Collection of Biological Samples From Patients With Rare Neurological Diseases","EXPLAINEUR","Inclusion Criteria:\n\n* all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and\u002For central nervous system symptoms.\n* Social coverage up to date.\n\nExclusion Criteria:\n\n* Patients with neurological damage from which the autoimmune character can be excluded.\n* Known anemia and hemoglobin \\\u003C10 g \u002F dl\n* Patients under protective supervision (guardianship, curators)\n* Pregnant or breastfeeding woman","6 Years",{"count":590,"type":22},1000,"The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.",[34],[594,595,596,597,598],"autoimmune encephalitis","paraneoplastic neurological syndrome","myasthenia","paraneoplastic cerebellar degeneration","rare neuropathologies with known\u002Fsuspected autoimmune origin","2026-03-16",{"date":601,"type":61},"2026-03-19",{"date":603,"type":61},"2020-10-12",{"date":605,"type":22},"2030-09-03",{"name":607,"class":140},"University Hospital, Toulouse",{"id":609,"slug":4,"hasResults":11,"nctId":610,"briefTitle":611,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":615,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":623,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":636,"locationsCount":179},"100337803","NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)","SMART","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;\n* Patients started their antidepressant treatment less than 5 days before inclusion;\n* Patient treated in an outpatient setting;\n* Patient informed of the diagnosis of his disease;\n* Informed patient with written consent.\n\nExclusion Criteria:\n\n* A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;\n* A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;\n* Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);\n* Non-comprehension of the French language","65 Years",{"count":617,"type":22},200,[154],"Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.",[621,622,349,300,34],"Depression","Psychiatric Disorder",[621,624,625,626,627,628,629,630],"Smartphone","Relapse prevention","Mobile support system","eHealth","Ecological","Randomized","Multicentric","2026-03-13",{"date":599,"type":61},{"date":634,"type":61},"2020-10-14",{"date":496,"type":22},{"name":637,"class":638},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":640,"slug":4,"hasResults":11,"nctId":641,"briefTitle":642,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":291,"sex":108,"minAge":645,"maxAge":646,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":649,"briefSummary":650,"conditions":651,"keywords":658,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":179},"100617877","NCT07324330","Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity","ALPHA-FIT","Inclusion Criteria:\n\niRBD:\n\n* Age: 50-80 years\n* Polysomnographically confirmed diagnosis of iRBD\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nHealthy controls:\n\n* Age: 50-80 years\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nExclusion Criteria:\n\niRBD:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n\nHealthy controls:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n* clinically diagnosed iRBD","50 Years","80 Years",{"count":648,"type":22},130,[154],"α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.\n\nThe aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.\n\nEighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the \"Deutsches Zentrum für Neurodegenerative Erkrankungen\" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.",[652,653,193,654,300,655,34,656,349,657],"Parkinson Disease","Prodromal Stage","Basal Ganglia Diseases","Synucleinopathies","Cerebral Disorder","Parkinsonian Disorders",[659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,203,679,680,681,682],"intervention","movement","iRBD","prodromal parkinson's","non-pharmacologic","alpha-synucleinopathy","biomarker","cognitive decline","executive function","MRI","lifestyle","prevention","RCT","motor decline","smartphone","smartwatch","accelerometer","scalable","prodromal","PD","Lewy-body","MSA","multiple system atrophy","dementia","2026-01-14",{"date":685,"type":61},"2026-01-16",{"date":687,"type":61},"2025-12-04",{"date":689,"type":22},"2029-12-01",{"name":691,"class":140},"University Hospital, Bonn",{"id":693,"slug":4,"hasResults":11,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":697,"eligibilityCriteria":698,"healthyVolunteers":291,"sex":108,"minAge":150,"maxAge":4,"enrollmentInfo":699,"targetDuration":4,"studyType":23,"phases":700,"briefSummary":701,"conditions":702,"keywords":703,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":706,"completionDateStruct":708,"leadSponsor":710,"locationsCount":179},"100534314","NCT06237218","Effects of the COTID (Community Occupational Therapist in Dementia) Program and Usual Occupational Therapy Care on Recurrence of Falls at 12 Months in Elderly People With Neurocognitive Disorders Who Had Been Hospitalized for Falls, After Their Return Home","Effets du Programme COTID (Community Occupational Therapist in Dementia) et d'Une Prise en Soins ergothérapique Habituelle Sur la récidive de Chutes à 12 Mois de Personnes âgées Atteintes de Troubles Neurocognitifs et Ayant été hospitalisées Pour Chute, après Leur Retour à Domicile","ErgoFalls","Inclusion Criteria:\n\n* Male or female, at least 75 years old\n* Living at home (excluding nursing home or long-term care facilities)\n* Hospitalized for fall\n* Presenting major mild to moderate dementia (MMSE \\> 16)\n* Accompanied by a caregiver with sufficient presence to meet study procedures: at investigator's discretion at the investigator's discretion\n* Having given free, informed and written consent signed by the patient\n* Whose caregiver has given free, informed consent written and signed by him\u002Fherself\n* Affiliated or beneficiary of social security\n\nExclusion Criteria:\n\n* With serious, life-threatening pathology(ies) or in palliative care\n* Participating in an educational fall program on the theme of falls, run by an occupational therapist by an occupational therapist\n* Receiving regular occupational therapy treatment on the day of inclusion (day care daily hospitalization)\n* Participating in a clinical research protocol have an impact on the occurrence of a fall (at the investigator's discretion)\n* Not matching with the fall definition from Kellogg's definition of a fall (loss of consciousness, sudden onset of paralysis paralysis or epileptic seizure)\n* Presenting a very significant post-fall syndrome:\n\nscore of 4\u002F4 on the \"Get-up early\" questionnaire\n\n* unable to read or write\n* Participant under legal guardianship (curator, guardian, legal protector)\n* Dementia with rapid neurocognitive degeneration degeneration with frontal and language impairment (at the investigator's discretion).",{"count":295,"type":22},[154],"This project will enable optimization of specific carried out by occupationist for older adults discharged from hospital for falls:\n\n* on the environmental dimension at the participant's home\n* on the involvement of the caregiver since they are also involved in the care of the patient\n* on the recurrence of falls and rehospitalizations in order to improve the quality of life by reassuring the elderly person when traveling\n* on limiting loss of autonomy and staying at home. The occupational therapist will entrust the caregiver with a support role. The participant will feel more involved in the participant's care (thus reducing the feeling of helplessness). His actions will allow him to strengthen his sense of competence and will prevent him from physical and psychological exhaustion.",[34],[212],"2026-01-12",{"date":683,"type":61},{"date":707,"type":61},"2024-07-29",{"date":709,"type":22},"2027-03-08",{"name":711,"class":140},"University Hospital, Limoges",{"id":713,"slug":4,"hasResults":11,"nctId":714,"briefTitle":715,"officialTitle":716,"acronym":4,"eligibilityCriteria":717,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":615,"enrollmentInfo":718,"targetDuration":4,"studyType":23,"phases":720,"briefSummary":721,"conditions":722,"keywords":736,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":739,"startDateStruct":740,"completionDateStruct":742,"leadSponsor":743,"locationsCount":179},"100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":719,"type":22},21,[154],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[723,349,724,34,300,122,725,726,727,728,729,730,731,732,733,734,735],"Headache Disorders, Secondary","Headache Disorders","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Pain","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[737,728,734],"Post-traumatic headache","2026-01-05",{"date":683,"type":61},{"date":741,"type":22},"2026-02",{"date":176,"type":22},{"name":744,"class":140},"Danish Headache Center",{"id":746,"slug":4,"hasResults":11,"nctId":747,"briefTitle":748,"officialTitle":749,"acronym":4,"eligibilityCriteria":750,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":615,"enrollmentInfo":751,"targetDuration":4,"studyType":23,"phases":752,"briefSummary":753,"conditions":754,"keywords":758,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":760,"startDateStruct":761,"completionDateStruct":762,"leadSponsor":764,"locationsCount":179},"100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":719,"type":22},[154],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[755,724,349,34,300,122,725,726,756,757,728,729,730,731,732,733,734,735],"Headache Disorders, Primary","Migraine Disorders","Headache",[759,757,728,734],"Migraine",{"date":683,"type":61},{"date":741,"type":22},{"date":763,"type":22},"2028-10-30",{"name":744,"class":140},{"id":766,"slug":4,"hasResults":11,"nctId":767,"briefTitle":768,"officialTitle":768,"acronym":769,"eligibilityCriteria":770,"healthyVolunteers":11,"sex":108,"minAge":4,"maxAge":4,"enrollmentInfo":771,"targetDuration":4,"studyType":23,"phases":772,"briefSummary":773,"conditions":774,"keywords":776,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":787,"startDateStruct":789,"completionDateStruct":791,"leadSponsor":793,"locationsCount":4},"100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":112,"type":22},[154],"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[195,512,244,349,300,34,775],"Vascular Disease",[777,778,779,200,780,781,782,783,784,785,195,786],"Mechanical Thrombectomy","Brain","Brain Clot","Brain Infarction","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology",{"date":788,"type":61},"2026-01-13",{"date":790,"type":22},"2026-01-01",{"date":792,"type":22},"2030-12-31",{"name":794,"class":68},"Gravity Medical Technology, INC",{"id":796,"slug":4,"hasResults":11,"nctId":797,"briefTitle":798,"officialTitle":798,"acronym":799,"eligibilityCriteria":800,"healthyVolunteers":11,"sex":108,"minAge":149,"maxAge":4,"enrollmentInfo":801,"targetDuration":4,"studyType":23,"phases":803,"briefSummary":804,"conditions":805,"keywords":807,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":816,"lastUpdatePostDateStruct":817,"startDateStruct":819,"completionDateStruct":821,"leadSponsor":823,"locationsCount":179},"100615113","NCT07288385","Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Upper Limb Recovery in Patients With Stroke","bi-tDCS+VR","Inclusion Criteria: 1- Adult participants (over 18 years of age) (Elsner et al., 2020).\n\n2- Patients with a unilateral cerebral infarction or haemorrhage who are at least three months post-stroke (Muller et al., 2021).\n\n3- Adequate mental status confirmed by an MMSE (Arabic version) should be ≥24 (Kim, 2021). ensuring the ability to comprehend and follow instructions.\n\n4- Modified Ashworth scale score \\\u003C 3 (Ögün et al., 2019). 5- Fugl-Meyer assessment (FMA) scores between 29 and 58, indicating moderate impairments (Woytowicz et al., 2017).\n\n\\-\n\nExclusion Criteria: - Visual impairment and severe hemisensory neglect or inattention (Stahl et al., 2019; Fluet1 et al., 2015).\n\n2- Individuals who have aphasia find it difficult to follow instructions (Fluet et al., 2015).\n\n3- Presence of any medical condition that contraindicates the use of non-invasive brain stimulation (Stahl et al., 2019; Learmonth et al., 2021).\n\n4- History of neurological disorders unrelated to stroke or participation in another study.\n\n\\-",{"count":802,"type":22},100,[154],"Following a stroke, the function of the distal upper limb, especially hand and finger movements, is often severely compromised, significantly restricting the ability to carry out daily activities. It is estimated that 55-75% of stroke survivors suffer from motor dysfunction, with upper limb impairments affecting up to 85% of them (Tang et al., 2024). Current rehabilitation approaches, while beneficial, often produce limited gains in hand function, particularly in patients with chronic stroke. Virtual reality (VR) training has emerged as a promising tool in neurorehabilitation, providing repetitive, task-specific, and engaging practice environments that can promote motor learning (Cameirão et al., 2012). tDCS has also shown potential to enhance motor recovery when combined with motor practice (Kang et al., 2016). To date, no studies have directly compared the effectiveness of Bi-tDCS with VR for improving upper limb function after stroke.",[349,300,34,195,806],"Paresis",[486,808,809,810,811,812,813,814,815,195],"Hemorrhagic stroke","bi-tDCS","Hemiparesis","Neural activation","Primary motor cortex","NIBS","Non-invasive brain stimulation","Transcranial direct current stimulation","2025-12-29",{"date":818,"type":61},"2025-12-30",{"date":820,"type":61},"2025-12-28",{"date":822,"type":22},"2027-01-30",{"name":824,"class":140},"King Saud University",{"id":826,"slug":4,"hasResults":11,"nctId":827,"briefTitle":828,"officialTitle":829,"acronym":830,"eligibilityCriteria":831,"healthyVolunteers":11,"sex":108,"minAge":447,"maxAge":4,"enrollmentInfo":832,"targetDuration":4,"studyType":23,"phases":834,"briefSummary":836,"conditions":837,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":850,"lastUpdatePostDateStruct":851,"startDateStruct":853,"completionDateStruct":855,"leadSponsor":857,"locationsCount":859},"100384702","NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial","CODEX","Inclusion Criteria:\n\n* Planned CABG (+\u002F- valve, including off-pump) or valve replacement via sternotomy\u002Fthoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)\n* Age ≥60\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Pre-operative major cognitive dysfunction (CogState Brief Battery score \\\u003C 80) at screening\n* Aortic arch replacement\u002Fre-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)\n* Allergy\u002Fcontraindication to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \\\u003C 50 , grade 4 LV, renal failure or on renal replacement therapy)\n* Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)",{"count":833,"type":22},2400,[835],"PHASE4","Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.",[838,839,840,455,841,842,121,122,34,725,843,844,845,846,847,848,849],"Delirium","Cognitive Dysfunction","Cognition Disorder","Mental Disorders","Confusion","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action","2025-11-27",{"date":852,"type":61},"2025-12-01",{"date":854,"type":61},"2019-12-01",{"date":856,"type":22},"2029-03",{"name":858,"class":140},"Sunnybrook Health Sciences Centre",8,""]